Call Options

3 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q4 2023

Jan 18, 2024

SELL
$3.58 - $6.25 $3,580 - $6,250
-1,000 Reduced 71.43%
400 $0
Q3 2023

Nov 07, 2023

BUY
$4.08 - $8.14 $5,712 - $11,396
1,400 New
1,400 $0
Q2 2022

Aug 04, 2022

BUY
$5.1 - $9.74 $509 - $974
100 New
100 $0

Others Institutions Holding CRBU

About Caribou Biosciences, Inc.


  • Ticker CRBU
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 60,840,800
  • Market Cap $118M
  • Description
  • Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1...
More about CRBU
Track This Portfolio

Track Cutler Group LP Portfolio

Follow Cutler Group LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

News

Stay updated on Cutler Group LP with notifications on news.